Financial Contrast: Krystal Biotech (KRYS) versus Its Rivals

Krystal Biotech (NASDAQ:KRYS) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Krystal Biotech to related businesses based on the strength of its institutional ownership, analyst recommendations, profitability, dividends, earnings, valuation and risk.

Profitability

This table compares Krystal Biotech and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	47.91%	17.02%	15.48%
Krystal Biotech Competitors	-12,359.35%	-203.09%	-30.93%

Volatility & Risk

Krystal Biotech has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Krystal Biotech’s competitors have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Krystal Biotech and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	1	1	10	2	2.93
Krystal Biotech Competitors	9846	15131	45507	1589	2.54

Krystal Biotech currently has a consensus target price of $375.00, suggesting a potential upside of 23.36%. As a group, “Biotechnology” companies have a potential upside of 100.27%. Given Krystal Biotech’s competitors higher possible upside, analysts clearly believe Krystal Biotech has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Krystal Biotech and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Krystal Biotech	$389.13 million	$204.83 million	41.25
Krystal Biotech Competitors	$698.13 million	$10.43 million	-15.35

Krystal Biotech’s competitors have higher revenue, but lower earnings than Krystal Biotech. Krystal Biotech is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Krystal Biotech beats its competitors on 10 of the 13 factors compared.

Krystal Biotech Company Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.